SCHEMBL24923905

SCHEMBL24923905

Cn1cc(C2=CC3CC(=O)CC3C2)cn1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.36
AURKA O14965 1/20 0.35
TTK P33981 1/20 0.35
AURKB Q96GD4 1/20 0.35
INCENP Q9NQS7 1/20 0.35
CREBBP Q92793 2/20 0.35
ACVR1 Q04771 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
KDM1A O60341 1/20 0.32
MKNK1 Q9BUB5 1/20 0.31
MKNK2 Q9HBH9 1/20 0.31
CHEK1 O14757 1/20 0.31
ERN1 O75460 1/20 0.31
PRMT5 O14744 2/20 0.30
WDR77 Q9BQA1 2/20 0.30
ACLY P53396 1/20 0.30
GRM2 Q14416 1/20 0.30
EPHX2 P34913 1/20 0.30
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14704639 0.76 IRAK4 (0.37) AURKATTKAURKBINCENPCHEK1
SCHEMBL7607611 0.70 CFTR (0.36)
SCHEMBL24923857 0.65 HCAR2 (0.42) BRD4CREBBPKDM5BKDM1A
SCHEMBL24924036 0.65
SCHEMBL13935679 0.64 BRD4 (0.41) BRD4AURKATTKAURKBINCENP
SCHEMBL28038031 0.61 MKNK1 (0.49) BRD4AURKATTKAURKBINCENP
SCHEMBL13492148 0.61 BRD4 (0.40) BRD4AURKATTKAURKBINCENP
SCHEMBL678929 0.61 BRD4 (0.40) BRD4AURKATTKAURKBINCENP
SCHEMBL26774057 0.61 AURKA (0.36) BRD4AURKATTKAURKBINCENP
SCHEMBL26773882 0.60 CREBBP (0.38) BRD4AURKATTKAURKBINCENP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2024-07-09 US disclosed
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2024-07-09 US disclosed
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2023-01-24 US disclosed
CN-113195055-A 5-membered heteroaryl carboxamide compounds for HBV therapy 组装生物科学股份有限公司 2021-07-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV HCCS, HAVCR2, MAVS BRD4 32/4885AURKA 1801/4885TTK 3287/4885
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV HCCS, HAVCR2, MAVS BRD4 32/4885AURKA 1801/4885TTK 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.